Prelude Capital Management’s Chembio diagnostics, Inc. CEMI Stock Holding History

Prelude Capital Management’s Portfolio CEMI Stock Details CEMI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-52,252	Closed	-$170K	–	2637
2020 Q2	$170K	Buy	+52,252	New	+$496K	0.01%	785
2019 Q2	–	Sell	-260	Closed	-$1K	–	2386
2019 Q1	$1K	Buy	+260	New	+$1.69K	﹤0.01%	1716
2018 Q3	–	Sell	-800	Closed	-$9K	–	2249
2018 Q2	$9K	Buy	+800	New	+$7.2K	﹤0.01%	1512

Other funds holding CEMI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SBH

Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Prelude Capital Management's CEMI Position: Q3 2020 in Review

Prelude Capital Management sold out of Chembio diagnostics, Inc. (CEMI) in Q3 2020, closing a stake of 52,252 shares — an estimated $170K sold.

Prelude Capital Management first reported a position in CEMI in Q2 2018 and held it in 3 quarters. The position peaked at $170K in Q2 2020. 59 funds tracked by Wall St. Rank hold CEMI as of Q3 2020.

Prelude Capital Management reported no remaining Chembio diagnostics, Inc. position as of Q3 2020 after selling out during the quarter.
Prelude Capital Management sold 52,252 Chembio diagnostics, Inc. shares in Q3 2020, an estimated $170K.
Prelude Capital Management first reported a position in Chembio diagnostics, Inc. in Q2 2018 and held it in 3 quarters.
Prelude Capital Management's Chembio diagnostics, Inc. position peaked at $170K in Q2 2020.
59 funds tracked by Wall St. Rank held Chembio diagnostics, Inc. as of Q3 2020.

Based on Prelude Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.